دورية أكاديمية
Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands
| العنوان: | Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands |
|---|---|
| المؤلفون: | Rutger M. Schepp, Joanna Kaczorowska, Pieter G. M. van Gageldonk, Elsbeth D. M. Rouers, Elisabeth A. M. Sanders, Patricia C. J. Bruijning-Verhagen, Guy A. M. Berbers |
| المصدر: | Vaccines, Vol 11, Iss 12, p 1807 (2023) |
| بيانات النشر: | MDPI AG, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | RSV prophylaxis, palivizumab effectiveness, very preterm infants, RSV infection rates, gestational age, Medicine |
| الوصف: | Respiratory Syncytial Virus (RSV) poses a severe threat to infants, particularly preterm infants. Palivizumab, the standard preventive prophylaxis, is primarily utilized in high-risk newborns due to its cost. This study assessed palivizumab’s effectiveness in preventing RSV infections in predominantly very preterm infants during their first year of life. Serum samples from a prospective multicentre cohort study in the Netherlands were analyzed to assess RSV infection rates by measuring IgG levels against three RSV proteins: nucleoprotein, pre-fusion, and post-fusion protein. Infants were stratified based on gestational age (GA), distinguishing very preterm (≤32 weeks GA) from moderate/late preterm (>32 to ≤36 weeks GA). In very preterm infants, palivizumab prophylaxis significantly reduced infection rates (18.9% vs. 48.3% in the prophylaxis vs. non-prophylaxis group. Accounting for GA, sex, birth season, and birth weight, the prophylaxis group showed significantly lower infection odds. In infants with >32 to ≤36 weeks GA, the non-prophylaxis group (55.4%) showed infection rates similar to the non-prophylaxis ≤32-week GA group, despite higher maternal antibody levels in the moderate/late preterm infants. In conclusion, palivizumab prophylaxis significantly reduces RSV infection rates in very premature infants. Future research should explore clinical implications and reasons for non-compliance, and compare palivizumab with emerging prophylactics like nirsevimab aiming to optimize RSV prophylaxis and improve preterm infant outcomes. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 11121807 2076-393X |
| Relation: | https://www.mdpi.com/2076-393X/11/12/1807; https://doaj.org/toc/2076-393X |
| DOI: | 10.3390/vaccines11121807 |
| URL الوصول: | https://doaj.org/article/6e6ad2c1ba0a4307a1be5aafdc967748 |
| رقم الأكسشن: | edsdoj.6e6ad2c1ba0a4307a1be5aafdc967748 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 11121807 2076393X |
|---|---|
| DOI: | 10.3390/vaccines11121807 |